VIRX Stock Discussion

Viracta Therapeutics, Inc. Description

Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. It is developing nanatinostat, an oral combination therapy in combination with the antiviral agent valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma. The company was founded in 2007 and is headquartered in Cardiff, California.

Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Lymphoma Hematology Antiviral Drug Anatomical Pathology Seagen